BeStock  
Stocks › Biotechnology › ACAD

ACADIA Pharmaceuticals ACAD

US equityMarket cap rank #2441Biotechnology
$17.11 −$0.48 (-2.73%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.12 +0.06%
Open$17.47
Prev close$17.59
Day range$17.05 – $17.79
Volume1.90M
Market cap$2.96B
P/E (TTM)8.1
Dividend yield–

ACAD Stock News

Headlines matching ACADIA Pharmaceuticals or the ACAD ticker, most recent first.

  • CCORF Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $36Market news · 3 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $31 to $36Market news · 26 Sep 2026 · Direct mention
  • Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX) PositiveTipRanks · 25 Sep 2026 · Direct mention
  • Analysts' Top Healthcare Picks: Kyverna Therapeutics, Inc. (KYTX), ACADIA Pharmaceuticals (ACAD)TipRanks · 25 Sep 2026 · Direct mention
  • Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $26Market news · 5 Aug 2026 · Direct mention
  • BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $31 PositiveMarket news · 5 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $38Market news · 5 Aug 2026 · Direct mention
  • RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $37 PositiveMarket news · 5 Aug 2026 · Direct mention
  • Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38 PositiveMarket news · 25 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40Market news · 25 Aug 2026 · Direct mention
  • BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36Market news · 18 Aug 2026 · Direct mention
  • UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49Market news · 18 Aug 2026 · Direct mention
  • UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $49 PositiveMarket news · 17 Aug 2026 · Direct mention
  • Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 PositiveMarket news · 12 Aug 2026 · Direct mention
  • Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $39 PositiveMarket news · 10 Aug 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on ACAD.

Sign in to join the discussion.

Scroll to Top